Etsy to Present at Upcoming Investor Conferences
Get Alerts ETSY Hot Sheet
Join SI Premium – FREE
BROOKLYN, N.Y., Aug. 2, 2018 /PRNewswire/ -- Etsy, Inc. (Nasdaq: ETSY), the global marketplace for unique and creative goods, today announced that Josh Silverman, CEO and Rachel Glaser, CFO will participate in a question and answer session at the Oppenheimer 21st Annual Technology, Internet & Communications Conference in Boston, MA on August 8, 2018 at 1:05 p.m. ET. Also, Rachel Glaser, CFO will participate in a question and answer session at the Canaccord Genuity Growth Conference in Boston, MA on August 9, 2018 at 4:30 p.m. ET.
A live webcast and replay of the sessions will be available on Etsy's investor relations website at investors.etsy.com.
About EtsyEtsy, Inc. is the global marketplace for unique and creative goods. Our mission is to keep commerce human, and we're committed to using the power of business to strengthen communities and empower people. We connect millions of buyers and sellers from nearly every country in the world. Buyers come to Etsy to be inspired and delighted by items that are crafted and curated by creative entrepreneurs. For sellers, we offer a range of tools and services that address key business needs.
Etsy was founded in 2005 and is headquartered in Brooklyn, New York.
Investor Relations Contact: Etsy, Deb Wasser, Vice President, Investor Relations [email protected]orGabriel Ratcliff, Senior Manager, Investor Relations[email protected]
Media Relations Contact:Etsy, Kelly Clausen, Director, Corporate Communications[email protected]
View original content:http://www.prnewswire.com/news-releases/etsy-to-present-at-upcoming-investor-conferences-300689783.html
SOURCE Etsy, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sygnia Unveils Security Operations Center Hubs and Expands AI-Powered Cybersecurity Capabilities To Challenge Threat Attack Rise
- Superior Shower Doors Debuts High-End Frameless Installations in Bergen County
- First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share